Bev 2.0.

Biosimilars are a crucial avenue to combating the unwieldy power of Big Pharma in the era of targeted therapies. This trial aims to take down none other than bevacizumab itself from the throne of market exclusivity. This multi-national study enrolled 142 patients with metastatic colorectal cancer receiving first-line physician’s choice FOLFOX or FOLFIRI and randomized them to the addition of standard bevacizumab versus its biosimilar BEVZ92. The primary endpoint of bioequivalence (aka pharmacokinetics) was met, with impressive secondary endpoints (of pharmacodynamics) such as a median progression-free survival of 11 months in each arm. TBL: Be on the lookout for a more affordable bev-alternative for your patients, hopefully marketed under a catchier name than BEVZ92. | Romera, Lancet Gastroenterol Hepatol 2018

Comments

  1. I will be happy if you read my comment. I must say that I like all your posts and wait for new ones. That's because they seem so great and suitable for me. Thanks a ton for uploading your articles.
    jogos friv online
    friv school Games to play
    a10 best free online game


    ReplyDelete

Post a Comment

Popular Posts